AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Niagen Bioscience, Inc. Director's Dealing 2018

Jan 24, 2018

32418_dirs_2018-01-24_32d52287-6445-42db-8e4a-a2d80674675f.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ChromaDex Corp. (CDXC)
CIK: 0001386570
Period of Report: 2018-01-22

Reporting Person: Friedman Mark J (General Counsel)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-01-22	Stock Option (right to buy)	$5.65	A	500000	Acquired	2028-01-21	Common Stock (500000)	Direct

Footnotes

F1: One-third of the shares subject to the option vest on January 22, 2019, and the remaining shares subject to the option vest in a series of 24 equal monthly installments thereafter on each such vesting date.